We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+1.08%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$335M
AUM Growth
+$128M
(+62%)
Cap. Flow
+$125M
Cap. Flow
% of AUM
37.46%
Top 10 Holdings %
Top 10 Hldgs %
47.51%
Holding
207
New
53
Increased
79
Reduced
42
Closed
32
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$23.4M |
| 2 |
iShares 0-1 Year Treasury Bond ETF
SHV
|
+$12M |
| 3 |
ETP
Energy Transfer Partners L.p.
ETP
|
+$7.84M |
| 4 |
WPZ
Williams Partners L.P.
WPZ
|
+$6.77M |
| 5 |
EEP
Enbridge Energy Partners
EEP
|
+$5.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares 20+ Year Treasury Bond ETF
TLT
|
+$1.69M |
| 2 |
Williams Companies
WMB
|
+$1.69M |
| 3 |
ProShares Ultra 20+ Year Treasury
UBT
|
+$1.24M |
| 4 |
RPTP
RAPTOR PHARMACEUTICAL CORP COM STK (DE)
RPTP
|
+$1.02M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
+$989K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Energy | 57.29% |
| 2 | Healthcare | 12.14% |
| 3 | Utilities | 3.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
LUMO
151
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $242K | 0.07% |
2,616
-102
| -4% | -$11.5K |
|
|
ONCE
152
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $242K | 0.07% |
4,847
-434
| -8% | -$23.2K |
|
153
Celldex Therapeutics
CLDX
$2.77B
| $241K | 0.07% |
4,535
+566
| +14% | +$32.2K |
|
|
AVXS
154
DELISTED
AveXis, Inc. Common Stock
AVXS
| $241K | 0.07% |
5,049
-820
| -14% | -$43.8K |
|
155
TG Therapeutics
TGTX
$8.58B
| $238K | 0.07% |
51,122
+15,825
| +45% | +$92.8K |
|
|
KITE
156
DELISTED
Kite Pharma, Inc.
KITE
| $238K | 0.07% |
5,313
+424
| +9% | +$20.8K |
|
157
Prothena Corp
PRTA
$458M
| $236K | 0.07% |
4,795
-714
| -13% | -$39.4K |
|
|
RDUS
158
DELISTED
Radius Health, Inc.
RDUS
| $233K | 0.07% |
6,130
-856
| -12% | -$40.7K |
|
|
AIMT
159
DELISTED
Aimmune Therapeutics
AIMT
| $231K | 0.07% |
11,276
-8,225
| -42% | -$168K |
|
160
Lexicon Pharmaceuticals
LXRX
$1.02B
| $227K | 0.07% |
16,410
-1,239
| -7% | -$19.9K |
|
161
Neurocrine Biosciences
NBIX
$17.7B
| $227K | 0.07% |
5,854
+530
| +10% | +$24K |
|
|
GBT
162
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $227K | 0.07% |
15,719
+4,009
| +34% | +$70.4K |
|
|
BLUE
163
DELISTED
bluebird bio
BLUE
| $226K | 0.07% |
283
-193
| -41% | -$153K |
|
164
Puma Biotechnology
PBYI
$406M
| $226K | 0.07% |
7,366
-300
| -4% | -$13K |
|
165
PTC Therapeutics
PTCT
$6.37B
| $224K | 0.07% |
20,523
-14,326
| -41% | -$150K |
|
|
XLRN
166
DELISTED
Acceleron Pharma
XLRN
| $224K | 0.07% |
8,771
+1,861
| +27% | +$59K |
|
167
Minerva Neurosciences
NERV
$188M
| $221K | 0.07% |
2,352
-852
| -27% | -$87K |
|
168
Alnylam Pharmaceuticals
ALNY
$36.3B
| $219K | 0.07% |
5,857
+1,779
| +44% | +$74.5K |
|
169
Alaunos Therapeutics
TCRT
$4.74M
| $216K | 0.06% |
269
+1
| +0.4% | +$901 |
|
|
FOLD
170
DELISTED
Amicus Therapeutics
FOLD
| $215K | 0.06% |
43,256
+2,551
| +6% | +$17.7K |
|
171
Agios Pharmaceuticals
AGIO
$2.16B
| $199K | 0.06% |
4,764
-304
| -6% | -$16K |
|
172
Vanguard Health Care ETF
VHT
$18.2B
| $186K | 0.06% |
+1,465
| New | +$187K |
|
|
173
Williams Companies
WMB
$90.5B
| $144K | 0.04% |
4,619
-56,101
| -92% | -$1.69M |
|
|
CEMP
174
DELISTED
Cempra, Inc.
CEMP
| $101K | 0.03% |
35,893
+22,609
| +170% | +$274K |
|
175
Acadia Pharmaceuticals
ACAD
$4.25B
| – | – |
-15,878
| Closed | -$505K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2016 Portfolio in Review
As of Q4 2016, Virtus ETF Advisers held 207 positions worth $335M, up 62% from $207M the previous quarter. Its ten largest holdings account for 48% of the portfolio.
Virtus ETF Advisers deployed $125M of net new capital in Q4 2016, opening 53 new positions and adding to 79 existing holdings. Its largest new stake was State Street SPDR S&P 500 ETF Trust: 107,222 shares worth $24M.
By sector, the portfolio is most concentrated in Energy at 57% of assets, down from 64% a quarter earlier, followed by Healthcare and Utilities.
On the sell side, the largest reduction was Williams Companies, an estimated $1.69M trimmed.
- Virtus ETF Advisers's largest Q4 2016 buy was State Street SPDR S&P 500 ETF Trust: 107,222 shares worth $24M.
- Virtus ETF Advisers added most to Energy Transfer Partners L.p. in Q4 2016, an estimated $7.84M increase.
- Virtus ETF Advisers's biggest Q4 2016 reduction was Williams Companies, cutting an estimated $1.69M.
- Virtus ETF Advisers fully exited iShares 20+ Year Treasury Bond ETF in Q4 2016, selling an estimated $1.69M.
- Virtus ETF Advisers's ten largest holdings make up 48% of its $335M portfolio in Q4 2016.
- Virtus ETF Advisers opened 53 new positions and closed 32 in Q4 2016.
- Virtus ETF Advisers's portfolio value rose 62% quarter-over-quarter to $335M.
Based on Virtus ETF Advisers's 13F filing for Q4 2016, filed 14 Feb 2017.